Clinical trials
Active, not recruiting Immune System Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 9 |
| 2024 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 32 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| UNC Lineberger Comprehensive Cancer Center | 6 |
| Bristol-Myers Squibb | 2 |
| Center for International Blood and Marrow Transplant Research | 2 |
| National Cancer Institute (NCI) | 2 |
| Viatris Innovation GmbH | 2 |
| Alumis Inc | 1 |
| Anne-Sophie Brazeau | 1 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
| Aravax Pty Ltd | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immune System Diseases | 32 |
| Autoimmune Diseases | 14 |
| Lymphoproliferative Disorders | 9 |
| Immunoproliferative Disorders | 8 |
| Neoplasms | 8 |
| Lymphatic Diseases | 7 |
| Lymphoma | 7 |
| Connective Tissue Diseases | 6 |
| Lupus Erythematosus, Systemic | 6 |
| Neoplasms by Histologic Type | 6 |
Trials
Showing 76 to 32 of 32. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.